RAPP insider trading
HealthcareRapport Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Company website: www.rapportrx.com
RAPP insider activity at a glance
FilingIQ tracks 123 insider transactions for RAPP in filings since Jun 10, 2024. The most recent transaction is dated Sep 30, 2026.
Across the full history, 24 open-market purchases
and 89 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RAPP insider trades is 52.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RAPP Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for RAPP?
- FilingIQ tracks 123 Form 4 insider transactions for RAPP (Rapport Therapeutics, Inc.), covering filings from Jun 10, 2024 onwards. 21 of those are dated within the last 90 days.
- Are RAPP insiders net buyers or net sellers?
- Across the full Form 4 history for RAPP, 24 transactions (20%) were open-market purchases and 89 (72%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RAPP insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is RAPP in?
- Rapport Therapeutics, Inc. (RAPP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.38B.
Methodology & sources
Every RAPP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.